Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 148 | $89,764,876 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 4,059 | 69.56 | 282,344 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 200 | 68.03 | 13,606 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,312 | 71.02 | 93,178 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,400 | 70.16 | 98,224 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,400 | 69.38 | 97,132 | D |
27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 12,462 | 70.11 | 873,711 | D |
27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 9,528 | 69.45 | 661,720 | D |
27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 600 | 68.39 | 41,034 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 600 | 69.81 | 41,886 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 5,282 | 69.47 | 366,941 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 288 | 70.15 | 20,203 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 6,867 | 69.38 | 476,432 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 300 | 68.33 | 20,499 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 392 | 70.13 | 27,491 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 7,215 | 69.54 | 501,731 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 300 | 68.54 | 20,562 | D |
28 Feb 2024 19:41 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 27 Feb 2024 | Sale | 10,349 | 73.14 | 756,926 | D |
28 Feb 2024 19:41 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 27 Feb 2024 | Sale | 9,651 | 72.71 | 701,724 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 661 | 66.96 | 44,261 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 872 | 65.89 | 57,456 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 2,179 | 65.06 | 141,766 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 07 Mar 2024 | Sale | 2,722 | 66.86 | 181,993 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 07 Mar 2024 | Sale | 3,728 | 66.34 | 247,316 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 1,313 | 66.86 | 87,787 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 1,729 | 65.92 | 113,976 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 4,303 | 65.11 | 280,168 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 07 Mar 2024 | Sale | 4,496 | 66.95 | 301,007 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 07 Mar 2024 | Sale | 8,636 | 66.37 | 573,171 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Mar 2024 | Sale | 1,238 | 66.7 | 82,575 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Mar 2024 | Sale | 6,107 | 65.82 | 401,963 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 07 Mar 2024 | Sale | 220 | 66.81 | 14,698 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 07 Mar 2024 | Sale | 12,912 | 66.14 | 854,000 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 64 | 67.12 | 4,296 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 4,475 | 66.47 | 297,453 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 29 | 67.32 | 1,952 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 1,100 | 66.54 | 73,194 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 4,453 | 65.28 | 290,692 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 07 Mar 2024 | Sale | 6,618 | 66.93 | 442,943 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 07 Mar 2024 | Sale | 6,514 | 66.26 | 431,618 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 306 | 67.33 | 20,603 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 1,590 | 66.81 | 106,228 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 4,128 | 65.9 | 272,035 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 14,541 | 64.8 | 942,257 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 07 Mar 2024 | Sale | 8,754 | 66.93 | 585,905 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 07 Mar 2024 | Sale | 31,958 | 66.38 | 2,121,372 | D |
21 Jun 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 18 Jun 2024 | Sale | 11,109 | 76.07 | 845,062 | D |
21 Jun 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 18 Jun 2024 | Sale | 8,891 | 75.71 | 673,138 | D |
25 Jun 2024 18:04 | ITCI | Intra-Cellular Therapies Inc | RIGGS RORY B | Director | 24 Jun 2024 | Sale | 4,462 | 75.57 | 337,193 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)